3 Firms Lead Novo Nordisk's $3.3B Dicerna Buy
Davis Polk-led global health care company Novo Nordisk is paying $3.3 billion for Skadden and Goodwin client biopharmaceutical business Dicerna, according to an announcement Thursday....To view the full article, register now.
Already a subscriber? Click here to view full article